Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Comment by HARJAYon Apr 06, 2021 11:10am
180 Views
Post# 32941420

RE:Hmm...

RE:Hmm...Could people when they are refering to an article please copy the article in their post so that the rest of us can see what the person is talking about . 
Thanks

I presume this is the article you are talking about

Aphria (NASDAQ:APHA) Price Target Increased to $22.00 by Analysts at Stifel Nicolaus

TUESDAY, APRIL 6, 2021 | MARKETBEAT

Aphria (NASDAQ:APHA) had its target price hoisted by Stifel Nicolaus from $15.50 to $22.00 in a report issued on Tuesday, The Fly reports. The firm currently has a "hold" rating on the stock. Stifel Nicolaus' price objective would indicate a potential upside of 20.95% from the stock's previous close. The analysts noted that the move was a valuation call.

Several other equities research analysts also recently issued reports on APHA. Alliance Global Partners lifted their price target on shares of Aphria from $12.00 to $20.00 and gave the stock a "buy" rating in a research note on Friday, January 15th. Canaccord Genuity raised shares of Aphria from a "hold" rating to a "speculative buy" rating and lifted their price target for the stock from $11.00 to $17.50 in a research note on Friday, January 15th. Cantor Fitzgerald lifted their price target on shares of Aphria from $26.00 to $32.50 and gave the stock an "overweight" rating in a research note on Tuesday, February 16th. Zacks Investment Research raised shares of Aphria from a "strong sell" rating to a "hold" rating in a report on Monday, March 22nd. Finally, CIBC raised their price objective on shares of Aphria from $18.00 to $28.00 and gave the stock an "outperform" rating in a report on Monday, February 22nd. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of "Buy" and a consensus price target of $18.53.

 

<< Previous
Bullboard Posts
Next >>